Zacks Investment Research upgraded shares of ALEXANDRIA REAL (ARE) from UNDERPERFORM to NEUTRAL on January 30, 2013, with a target price of $74.50.
Alexandria Real Estate Equities, Inc., Landlord and Developer of Choice to the Life Science Industry, is a publicly-traded real estate investment trust focused principally on the ownership, operation, management, selective redevelopment, development and acquisition of life science properties. Our properties are designed and improved for lease primarily to institutional, pharmaceutical, biotechnology, medical device, life science product, service, biodefense and translational medicine entities, as well as governmental agencies.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on ALEXANDRIA REAL (ARE),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment